Intravascular histiocytosis of the skin
- Authors: Podverbnaya J.S.1, Bulanov D.V.1
-
Affiliations:
- FSAEI HE N.I. Pirogov RNRMU of MOH of Russia
- Section: DERMATOLOGY
- Submitted: 09.02.2025
- Accepted: 02.06.2025
- Published: 27.07.2025
- URL: https://rjsvd.com/1560-9588/article/view/653977
- DOI: https://doi.org/10.17816/dv653977
- ID: 653977
Cite item
Full Text



Abstract
Intravascular histiocytosis (IH) is a rare skin condition characterized by pathological dilation of blood vessels and the accumulation of histiocytes within their lumen. Despite its rarity, the issue of diagnosing and treating IH remains relevant due to the lack of standardized approaches and limited understanding of its developmental mechanisms. The key factor triggering the development of IH is vascular wall damage, which promotes the migration and proliferation of histiocytes within the vessels. This process may be caused by various factors, including infections, cardiovascular system disorders, and liver or kidney pathology. However, the disease can also occur in individuals without associated conditions, suggesting the presence of unknown triggers or genetic predispositions. The clinical manifestations of IH are diverse but most commonly localized on the trunk and extremities. Lesions often appear as papules and hemorrhagic nodules, complicating differential diagnosis with other dermatological diseases. The uniqueness of the symptoms and the rarity of the pathology often lead to misdiagnoses and inappropriate treatments, exacerbating the course of the disease. This article describes a clinical case of a patient with skin changes observed in the neck and scalp—an atypical site for IH manifestation. The lesions presented as papules and hemorrhagic nodules. The diagnosis was confirmed through dermatoscopy and histological examination of a skin biopsy. The treatment provided led to the complete resolution of clinical manifestations, with no recurrence of the disease observed. Currently, there is no universal protocol for treating IH. Steroidal drugs are often employed as one therapeutic strategy; however, their efficacy and long-term outcomes remain insufficiently studied. The presented case highlights the importance of further research in IH to develop unified diagnostic and therapeutic approaches. Advancing the understanding of the disease mechanisms and creating treatment standards will improve patients' chances of full recovery and enhance prognosis for this pathology.
Full Text

About the authors
Julia S. Podverbnaya
FSAEI HE N.I. Pirogov RNRMU of MOH of Russia
Author for correspondence.
Email: julia_123_julia_123@mail.ru
ORCID iD: 0009-0002-9236-6714
cтудент
Russian FederationDmitry V. Bulanov
FSAEI HE N.I. Pirogov RNRMU of MOH of Russia
Email: dbulanov81@gmail.com
ORCID iD: 0009-0005-3772-6643
SPIN-code: 2641-6658
MD. Cand. Sci. (Med.), Associate Professor
Russian FederationReferences
- Demirkesen C, Kran T, Leblebici C, Yücelten D, Aksu AE, Mat C. Intravascular/Intralymphatic Histiocytosis: A Report of 3 Cases. Am J Dermatopathol.2015 Oct;37(10):783-9. doi: 10.1097/DAD.0000000000000257.
- O'Grady JT, Shahidullah H, Doherty VR, al-Nafussi A. Intravascular histiocytosis. Histopathology. 1994 Mar;24(3):265-8. doi: 10.1111/j.1365- 2559.1994.tb00519.x.
- Rieger E, Soyer HP, Leboit PE, Metze D, Slovak R, Kerl H. Reactive angioendotheliomatosis or intravascular histiocytosis? An immunohistochemical and ultrastructural study in two cases of intravascular histiocytic cell proliferation. Br J Dermatol. 1999 Mar;140(3):497-504. doi: 10.1046/j.1365-2133.1999.02717.x.
- Asagoe K, Torigoe R, Ofuji R, Iwatsuki K. Reactive intravascular histiocytosis associated with tonsillitis. Br J Dermatol. 2006 Mar;154(3):560-3. doi: 10.1111/j.1365-2133.2005.07089.x.
- Catalina-Fernández I, Alvárez AC, Martin FC, Fernández-Mera JJ, SáenzSantamaría J. Cutaneous intralymphatic histiocytosis associated with rheumatoid arthritis: report of a case and review of the literature. Am J Dermatopathol. 2007 Apr;29(2):165-8. doi: 10.1097/01.dad.0000251824.09384.46.
- Lichtenstein L. Histiocytosis X; integration of eosinophilic granuloma of bone, Letterer-Siwe disease, and Schüller-Christian disease as related manifestations of a single nosologic entity. AMA Arch Pathol. 1953;56(1):84–102.
- Hamre M, Hedberg J, Buckley J, Bhatia S, Finlay J, Meadows A, Nesbit M, Smithson A, Robison L. Langerhans cell histiocytosis: an exploratory epidemiologic study of 177 cases. Med Pediatr Oncol. 1997 Feb;28(2):92-7. doi: 10.1002/(sici)1096-911x(199702)28:2<92::aid-mpo2>3.0.co;2-n.
- McClain K, Jin H, Gresik V, Favara B. Langerhans cell histiocytosis: lack of a viral etiology. Am J Hematol. 1994;47(1):16–20. doi: 10.1002/ajh.2830470104.
- Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet. 1994;343(8900):767–768. doi: 10.1016/s0140-6736(94)91842-2.
- Lim KPH, Milne P, Poidinger M, Duan K, Lin H, McGovern N, Abhyankar H, Zinn D, Burke TM, Eckstein OS, Chakraborty R, Sengal A, Scull B, Newell E, Merad M, McClain KL, Man TK, Ginhoux F, Collin M, Allen CE. Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Blood Adv. 2020 Jan 14;4(1):87-99. doi: 10.1182/bloodadvances.2019000488.
- Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–1923. doi: 10.1182/blood-2010-04-279083.
- Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, Chakraborty R, Leboeuf M, Beltrão M, Lira SA, Heym KM, Bigley V, Collin M, Manz MG, McClain K, Merad M, Allen CE. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669–683. doi: 10.1084/jem.20130977.
- Cui L, Zhang L, Ma HH, Wang CJ, Wang D, Lian HY, Li WJ, Zhang Q, Li N, Wang TY, Li ZG, Zhang R. Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis. Haematologica. 2020;105(9):e444–447. doi: 10.3324/haematol.2019.229187.
- Okamoto N, Tanioka M, Yamamoto T, Shiomi T, Miyachi Y, Utani A. Intralymphatic histiocytosis associated with rheumatoid arthritis. Clin Exp Dermatol. 2008 Jul;33(4):516-8. doi: 10.1111/j.1365-2230.2008.02735.x. Epub 2008 May 15.
- Requena L, El-Shabrawi-Caelen L, Walsh SN, Segura S, Ziemer M, Hurt MA, Sangüeza OP, Kutzner H. Intralymphatic histiocytosis. A clinicopathologic study of 16 cases. Am J Dermatopathol. 2009 Apr;31(2):140- 51. doi: 10.1097/DAD.0b013e3181986cc2.
- Abuawad YG, Diniz TACB, Kakizaki P, Valente NYS. Intravascular histiocytosis: case report of a rare disease probably associated with silicone breast implant. An Bras Dermatol. 2020 May-Jun;95(3):347-350. doi: 10.1016/j.abd.2019.04.016. Epub 2020 Mar 19.
- Requena L, Fariña MC, Renedo G, Alvarez A, Yus ES, Sangueza OP. Intravascular and diffuse dermal reactive angioendotheliomatosis secondary to iatrogenic arteriovenous fistulas. J Cutan Pathol. 1999 Mar;26(3):159-64. doi: 10.1111/j.1600-0560.1999.tb01822.x.
- Rhee DY, Lee DW, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK, Lee SJ. Intravascular histiocytosis without rheumatoid arthritis. J Dermatol. 2008 Oct;35(10):691-3. doi: 10.1111/j.1346-8138.2008.00544.x.
- Aung PP, Ballester LY, Goldberg LJ, Bhawan J. Incidental simultaneous finding of intravascular histiocytosis and reactive angioendotheliomatosis: a case report. Am J Dermatopathol. 2015 May;37(5):401-4. doi: 10.1097/DAD.0000000000000244.
- Takiwaki H, Adachi A, Kohno H, Ogawa Y. Intravascular or intralymphatic histiocytosis associated with rheumatoid arthritis: a report of 4 cases. J Am Acad Dermatol. 2004 Apr;50(4):585-90. doi: 10.1016/j.jaad.2003.09.025.
- Mazloom SE, Stallings A, Kyei A. Differentiating Intralymphatic Histiocytosis, Intravascular Histiocytosis, and Subtypes of Reactive Angioendotheliomatosis: Review of Clinical and Histologic Features of All Cases Reported to Date. Am J Dermatopathol. 2017 Jan;39(1):33-39. doi: 10.1097/DAD.0000000000000574.
- Nishie W, Sawamura D, Iitoyo M, Shimizu H. Intravascular histiocytosis associated with rheumatoid arthritis. Dermatology. 2008;217(2):144-5. doi: 10.1159/000135630. Epub 2008 May 29.
- Gorlanov I.A., Zaslavsky D.V., Mineyeva O.K., Leina L.M., Milyavskaya I.R., Peredereyev S.S., Bolshakova Y.S. Langerhans cell histiocytosis (histiocytosis x): a case study // Vestnik dermatologii i venerologii. - 2013. - Vol. 89. - N. 1. - P. 51-55. doi: 10.25208/vdv601
- Bakr F, Webber N, Fassihi H, Swale V, Lewis F, Rytina E, Ben-Zvi GT, Norris P, Espinosa O, Dhar S, Craig P, Robson A. Primary and secondary intralymphatic histiocytosis. J Am Acad Dermatol. 2014 May;70(5):927-33. doi: 10.1016/j.jaad.2013.11.024. Epub 2014 Jan 17.
- Mensing CH, Krengel S, Tronnier M, Wolff HH. Reactive angioendotheliomatosis: is it 'intravascular histiocytosis'? J Eur Acad Dermatol Venereol. 2005 Mar;19(2):216-9. doi: 10.1111/j.1468-3083.2005.01009.x.
Supplementary files
